Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis
Summary Background : Steroid resistance represents a major clinical problem in the treatment of ulcerative colitis. In vitro, interleukin‐2 renders lymphocytes steroid resistant. Aim : To explore the therapeutic potential of interleukin‐2 receptor blockade in steroid‐resistant ulcerative colitis wit...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2003-07, Vol.18 (1), p.65-75 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 75 |
|---|---|
| container_issue | 1 |
| container_start_page | 65 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 18 |
| creator | Creed, T. J. Norman, M. R. Probert, C. S. J. Harvey, R. F. Shaw, I. S. Smithson, J. Anderson, J. Moorghen, M. Gupta, J. Shepherd, N. A. Dayan, C. M. Hearing, S. D. |
| description | Summary
Background : Steroid resistance represents a major clinical problem in the treatment of ulcerative colitis. In vitro, interleukin‐2 renders lymphocytes steroid resistant.
Aim : To explore the therapeutic potential of interleukin‐2 receptor blockade in steroid‐resistant ulcerative colitis with both in vitro measures and a pilot in vivo study.
Methods : Ten patients with steroid‐resistant ulcerative colitis received a single bolus of 40 mg of intravenous basiliximab plus steroid treatment in an open‐label, uncontrolled, 24‐week study. The outcome was assessed using the Ulcerative Colitis Symptom Score, rectal biopsy and Inflammatory Bowel Disease Questionnaire. Lymphocyte steroid sensitivity was measured in vitro in 39 subjects in the presence or absence of basiliximab.
Results : Nine of the 10 patients achieved clinical remission within 8 weeks. At 24 weeks, seven patients were in clinical remission. Marked improvement in the Ulcerative Colitis Symptom Score was seen by 1 week (P = 0.004) and on rectal biopsy and Inflammatory Bowel Disease Questionnaire by 2 weeks (both P |
| doi_str_mv | 10.1046/j.1365-2036.2003.01639.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73449242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73449242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4479-f6332273c79867bdd2c2467ac37b0ad342fb7168dee580eda8cfb75a443e3d473</originalsourceid><addsrcrecordid>eNqNkc1u1DAUha0K1A6lr1B5AyqLBMd27GTRRTv8SpVgUdbWjXMjPEqc1vZ0ZnZIvADPyJOQdAa6ZeUr3-8cW-cQQguWF0yqt6u8EKrMOBMq54yJnBVK1Pn2iCz-LZ6RBeOqznhViBPyIsYVY0xpxo_JScErWSmuF-TnNUTXu60boKEX4JP7_ePX8h0v31DnqR2HxnlIbvR049J3GhOG0bWRDrCjDVLwFLsObXIPSD1uaAoIaUCfaDeGv_hkGTC6mCZ_uu4tBngU2LF3ycWX5HkHfcSzw3lKvn14f7v8lN18-fh5eXWTWSl1nXVKCM61sLqulG7allsulQYrdMOgFZJ3jS5U1SKWFcMWKjtdlCClQNFKLU7J673vXRjv1xiTGVy02PfgcVxHo4WUNZd8Aqs9aMMYY8DO3IUpoLAzBTNzAWZl5pzNnLOZCzCPBZjtJD0_vLFuBmyfhIfEJ-DVAYBooe8CeOviEydrqVlZTtzlntu4Hnf__QFz9fV2nsQfXfylDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73449242</pqid></control><display><type>article</type><title>Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis</title><source>MEDLINE</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Creed, T. J. ; Norman, M. R. ; Probert, C. S. J. ; Harvey, R. F. ; Shaw, I. S. ; Smithson, J. ; Anderson, J. ; Moorghen, M. ; Gupta, J. ; Shepherd, N. A. ; Dayan, C. M. ; Hearing, S. D.</creator><creatorcontrib>Creed, T. J. ; Norman, M. R. ; Probert, C. S. J. ; Harvey, R. F. ; Shaw, I. S. ; Smithson, J. ; Anderson, J. ; Moorghen, M. ; Gupta, J. ; Shepherd, N. A. ; Dayan, C. M. ; Hearing, S. D.</creatorcontrib><description>Summary
Background : Steroid resistance represents a major clinical problem in the treatment of ulcerative colitis. In vitro, interleukin‐2 renders lymphocytes steroid resistant.
Aim : To explore the therapeutic potential of interleukin‐2 receptor blockade in steroid‐resistant ulcerative colitis with both in vitro measures and a pilot in vivo study.
Methods : Ten patients with steroid‐resistant ulcerative colitis received a single bolus of 40 mg of intravenous basiliximab plus steroid treatment in an open‐label, uncontrolled, 24‐week study. The outcome was assessed using the Ulcerative Colitis Symptom Score, rectal biopsy and Inflammatory Bowel Disease Questionnaire. Lymphocyte steroid sensitivity was measured in vitro in 39 subjects in the presence or absence of basiliximab.
Results : Nine of the 10 patients achieved clinical remission within 8 weeks. At 24 weeks, seven patients were in clinical remission. Marked improvement in the Ulcerative Colitis Symptom Score was seen by 1 week (P = 0.004) and on rectal biopsy and Inflammatory Bowel Disease Questionnaire by 2 weeks (both P < 0.05). Improvements persisted to 24 weeks (Ulcerative Colitis Symptom Score, Inflammatory Bowel Disease Questionnaire, both P < 0.005). Eight of the nine responders relapsed (median, 9 weeks), but remission was re‐achieved with further corticosteroids and the addition of azathioprine. At 24 weeks, seven patients were in full clinical remission, five off all steroid therapy. In vitro measurement of lymphocyte steroid sensitivity demonstrated steroid resistance in 22% of subjects. All were rendered steroid sensitive in the presence of basiliximab.
Conclusions : Basiliximab appears to be effective at inducing remission in steroid‐resistant ulcerative colitis. In vitro, basiliximab also produced a dramatic increase in lymphocyte steroid sensitivity in healthy subjects. Confirmation in randomized controlled studies is required.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.2003.01639.x</identifier><identifier>PMID: 12848627</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - therapeutic use ; Basiliximab ; Biological and medical sciences ; Colitis, Ulcerative - drug therapy ; Drug Combinations ; Drug Resistance ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Recombinant Fusion Proteins ; Remission Induction ; Steroids - therapeutic use ; Treatment Outcome</subject><ispartof>Alimentary pharmacology & therapeutics, 2003-07, Vol.18 (1), p.65-75</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4479-f6332273c79867bdd2c2467ac37b0ad342fb7168dee580eda8cfb75a443e3d473</citedby><cites>FETCH-LOGICAL-c4479-f6332273c79867bdd2c2467ac37b0ad342fb7168dee580eda8cfb75a443e3d473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2036.2003.01639.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2036.2003.01639.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14947055$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12848627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Creed, T. J.</creatorcontrib><creatorcontrib>Norman, M. R.</creatorcontrib><creatorcontrib>Probert, C. S. J.</creatorcontrib><creatorcontrib>Harvey, R. F.</creatorcontrib><creatorcontrib>Shaw, I. S.</creatorcontrib><creatorcontrib>Smithson, J.</creatorcontrib><creatorcontrib>Anderson, J.</creatorcontrib><creatorcontrib>Moorghen, M.</creatorcontrib><creatorcontrib>Gupta, J.</creatorcontrib><creatorcontrib>Shepherd, N. A.</creatorcontrib><creatorcontrib>Dayan, C. M.</creatorcontrib><creatorcontrib>Hearing, S. D.</creatorcontrib><title>Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background : Steroid resistance represents a major clinical problem in the treatment of ulcerative colitis. In vitro, interleukin‐2 renders lymphocytes steroid resistant.
Aim : To explore the therapeutic potential of interleukin‐2 receptor blockade in steroid‐resistant ulcerative colitis with both in vitro measures and a pilot in vivo study.
Methods : Ten patients with steroid‐resistant ulcerative colitis received a single bolus of 40 mg of intravenous basiliximab plus steroid treatment in an open‐label, uncontrolled, 24‐week study. The outcome was assessed using the Ulcerative Colitis Symptom Score, rectal biopsy and Inflammatory Bowel Disease Questionnaire. Lymphocyte steroid sensitivity was measured in vitro in 39 subjects in the presence or absence of basiliximab.
Results : Nine of the 10 patients achieved clinical remission within 8 weeks. At 24 weeks, seven patients were in clinical remission. Marked improvement in the Ulcerative Colitis Symptom Score was seen by 1 week (P = 0.004) and on rectal biopsy and Inflammatory Bowel Disease Questionnaire by 2 weeks (both P < 0.05). Improvements persisted to 24 weeks (Ulcerative Colitis Symptom Score, Inflammatory Bowel Disease Questionnaire, both P < 0.005). Eight of the nine responders relapsed (median, 9 weeks), but remission was re‐achieved with further corticosteroids and the addition of azathioprine. At 24 weeks, seven patients were in full clinical remission, five off all steroid therapy. In vitro measurement of lymphocyte steroid sensitivity demonstrated steroid resistance in 22% of subjects. All were rendered steroid sensitive in the presence of basiliximab.
Conclusions : Basiliximab appears to be effective at inducing remission in steroid‐resistant ulcerative colitis. In vitro, basiliximab also produced a dramatic increase in lymphocyte steroid sensitivity in healthy subjects. Confirmation in randomized controlled studies is required.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Basiliximab</subject><subject>Biological and medical sciences</subject><subject>Colitis, Ulcerative - drug therapy</subject><subject>Drug Combinations</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Recombinant Fusion Proteins</subject><subject>Remission Induction</subject><subject>Steroids - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUha0K1A6lr1B5AyqLBMd27GTRRTv8SpVgUdbWjXMjPEqc1vZ0ZnZIvADPyJOQdAa6ZeUr3-8cW-cQQguWF0yqt6u8EKrMOBMq54yJnBVK1Pn2iCz-LZ6RBeOqznhViBPyIsYVY0xpxo_JScErWSmuF-TnNUTXu60boKEX4JP7_ePX8h0v31DnqR2HxnlIbvR049J3GhOG0bWRDrCjDVLwFLsObXIPSD1uaAoIaUCfaDeGv_hkGTC6mCZ_uu4tBngU2LF3ycWX5HkHfcSzw3lKvn14f7v8lN18-fh5eXWTWSl1nXVKCM61sLqulG7allsulQYrdMOgFZJ3jS5U1SKWFcMWKjtdlCClQNFKLU7J673vXRjv1xiTGVy02PfgcVxHo4WUNZd8Aqs9aMMYY8DO3IUpoLAzBTNzAWZl5pzNnLOZCzCPBZjtJD0_vLFuBmyfhIfEJ-DVAYBooe8CeOviEydrqVlZTtzlntu4Hnf__QFz9fV2nsQfXfylDQ</recordid><startdate>200307</startdate><enddate>200307</enddate><creator>Creed, T. J.</creator><creator>Norman, M. R.</creator><creator>Probert, C. S. J.</creator><creator>Harvey, R. F.</creator><creator>Shaw, I. S.</creator><creator>Smithson, J.</creator><creator>Anderson, J.</creator><creator>Moorghen, M.</creator><creator>Gupta, J.</creator><creator>Shepherd, N. A.</creator><creator>Dayan, C. M.</creator><creator>Hearing, S. D.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200307</creationdate><title>Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis</title><author>Creed, T. J. ; Norman, M. R. ; Probert, C. S. J. ; Harvey, R. F. ; Shaw, I. S. ; Smithson, J. ; Anderson, J. ; Moorghen, M. ; Gupta, J. ; Shepherd, N. A. ; Dayan, C. M. ; Hearing, S. D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4479-f6332273c79867bdd2c2467ac37b0ad342fb7168dee580eda8cfb75a443e3d473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Basiliximab</topic><topic>Biological and medical sciences</topic><topic>Colitis, Ulcerative - drug therapy</topic><topic>Drug Combinations</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Recombinant Fusion Proteins</topic><topic>Remission Induction</topic><topic>Steroids - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Creed, T. J.</creatorcontrib><creatorcontrib>Norman, M. R.</creatorcontrib><creatorcontrib>Probert, C. S. J.</creatorcontrib><creatorcontrib>Harvey, R. F.</creatorcontrib><creatorcontrib>Shaw, I. S.</creatorcontrib><creatorcontrib>Smithson, J.</creatorcontrib><creatorcontrib>Anderson, J.</creatorcontrib><creatorcontrib>Moorghen, M.</creatorcontrib><creatorcontrib>Gupta, J.</creatorcontrib><creatorcontrib>Shepherd, N. A.</creatorcontrib><creatorcontrib>Dayan, C. M.</creatorcontrib><creatorcontrib>Hearing, S. D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Creed, T. J.</au><au>Norman, M. R.</au><au>Probert, C. S. J.</au><au>Harvey, R. F.</au><au>Shaw, I. S.</au><au>Smithson, J.</au><au>Anderson, J.</au><au>Moorghen, M.</au><au>Gupta, J.</au><au>Shepherd, N. A.</au><au>Dayan, C. M.</au><au>Hearing, S. D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2003-07</date><risdate>2003</risdate><volume>18</volume><issue>1</issue><spage>65</spage><epage>75</epage><pages>65-75</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background : Steroid resistance represents a major clinical problem in the treatment of ulcerative colitis. In vitro, interleukin‐2 renders lymphocytes steroid resistant.
Aim : To explore the therapeutic potential of interleukin‐2 receptor blockade in steroid‐resistant ulcerative colitis with both in vitro measures and a pilot in vivo study.
Methods : Ten patients with steroid‐resistant ulcerative colitis received a single bolus of 40 mg of intravenous basiliximab plus steroid treatment in an open‐label, uncontrolled, 24‐week study. The outcome was assessed using the Ulcerative Colitis Symptom Score, rectal biopsy and Inflammatory Bowel Disease Questionnaire. Lymphocyte steroid sensitivity was measured in vitro in 39 subjects in the presence or absence of basiliximab.
Results : Nine of the 10 patients achieved clinical remission within 8 weeks. At 24 weeks, seven patients were in clinical remission. Marked improvement in the Ulcerative Colitis Symptom Score was seen by 1 week (P = 0.004) and on rectal biopsy and Inflammatory Bowel Disease Questionnaire by 2 weeks (both P < 0.05). Improvements persisted to 24 weeks (Ulcerative Colitis Symptom Score, Inflammatory Bowel Disease Questionnaire, both P < 0.005). Eight of the nine responders relapsed (median, 9 weeks), but remission was re‐achieved with further corticosteroids and the addition of azathioprine. At 24 weeks, seven patients were in full clinical remission, five off all steroid therapy. In vitro measurement of lymphocyte steroid sensitivity demonstrated steroid resistance in 22% of subjects. All were rendered steroid sensitive in the presence of basiliximab.
Conclusions : Basiliximab appears to be effective at inducing remission in steroid‐resistant ulcerative colitis. In vitro, basiliximab also produced a dramatic increase in lymphocyte steroid sensitivity in healthy subjects. Confirmation in randomized controlled studies is required.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12848627</pmid><doi>10.1046/j.1365-2036.2003.01639.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2003-07, Vol.18 (1), p.65-75 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73449242 |
| source | MEDLINE; Wiley Free Content; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Adult Aged Antibodies, Monoclonal - therapeutic use Basiliximab Biological and medical sciences Colitis, Ulcerative - drug therapy Drug Combinations Drug Resistance Female Humans Immunosuppressive Agents - therapeutic use Male Medical sciences Middle Aged Recombinant Fusion Proteins Remission Induction Steroids - therapeutic use Treatment Outcome |
| title | Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T13%3A07%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Basiliximab%20(anti%E2%80%90CD25)%20in%20combination%20with%20steroids%20may%20be%20an%20effective%20new%20treatment%20for%20steroid%E2%80%90resistant%20ulcerative%20colitis&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Creed,%20T.%20J.&rft.date=2003-07&rft.volume=18&rft.issue=1&rft.spage=65&rft.epage=75&rft.pages=65-75&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.2003.01639.x&rft_dat=%3Cproquest_cross%3E73449242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73449242&rft_id=info:pmid/12848627&rfr_iscdi=true |